Connect with us

Business

Pfizer boosts obesity drug prospects with $7.3 billion deal to buy Metsera

Published

on

Pfizer boosts obesity drug prospects with .3 billion deal to buy Metsera


Thomas Fuller | SOPA Images | Lightrocket | Getty Images

Pfizer on Monday said it would buy weight loss drugmaker Metsera in an up to $7.3 billion deal, including future payments, as it scrambles to win a slice in the booming obesity drug market. 

Pfizer said it will pay an initial $47.50 a share in cash for Metsera, a nearly 43% premium to the biotech company’s Friday’s closing price of $33.32. That gives the deal an enterprise value of $4.9 billion. 

The pact also includes a contingent value right worth up to $22.50 a share based on potential clinical and regulatory achievements for Metsera’s medicines, which could bring the total value to $70 a share. 

The deal is expected to close at the end of the year. Shares of Metsera rose more than 60% in premarket trading on Monday, while Pfizer’s stock rose more than 1%. 

The move comes after a string of setbacks for Pfizer in the obseity space. The pharmaceutical giant struggled to develop its own lead obesity drug candidate, danuglipron, before deciding to scrap it entirely in April due to safety concerns. Pfizer also discontinued a different once-daily pill in June 2023 due to elevated liver enzymes in patients who received it. 

Pfizer has earlier-stage obesity drugs in its pipeline that work in different ways, but the company has faced mounting investor pressure to accelerate its push into the market.

The opportunity could be huge. Some analysts expect the weight loss drug space could be worth roughly $100 billion by the 2030s, with room for new rivals to compete with popular injections from Eli Lilly and Novo Nordisk.

Metsera, founded in 2022, brings a pipeline of both oral and injectable treatments with different targets that the company had picked up through its own licensing and acquisition deals. That includes a GLP-1 drug called MET-233i, which helped patients lose up to 8.4% of their weight in 36 days in a small, early-stage trial. Metsera is developing that treatment as a potential once-monthly injectable, meaning that patients can take it less frequently than existing weekly injections.

Metsera’s pipeline also includes a monthly drug targeting a hormone called amylin, along with two oral GLP-1 candidates “expected to begin trials imminently,” Pfizer said in a release. 

“The proposed acquisition of Metsera aligns with our focus on directing our investments to the most impactful opportunities and propels Pfizer into this key therapeutic area,” Pfizer CEO Albert Bourla said in a statement. “We are excited to apply our deep cardiometabolic experience and manufacturing and commercial infrastructure to accelerate a portfolio that includes potential best-in-class injectables.”

In a note on Monday, Leerink Partners analyst David Risinger said the firm estimates Metsera’s obesity candidates have the potential to generate more than $5 billion in combined peak annual sales. In a separate note on Monday, JPMorgan analyst Chris Schott said Metsera’s experimental drugs “should accelerate” Pfizer’s entry into the market. 

The New York-based Metsera went public this year in one of the biggest biotech listings of 2025. It is among several companies racing to develop next-generation obesity treatments following the success of weekly injections such as Eli Lilly’s obesity drug Zepbound and Novo Nordisk’s rival Wegovy. 



Source link

Business

Iran war: Asia stocks jump after Trump suggests conflict could end in weeks

Published

on

Iran war: Asia stocks jump after Trump suggests conflict could end in weeks



The price of Brent crude oil to be delivered in May rose by a record 64% in March as the conflict disrupted energy supplies.



Source link

Continue Reading

Business

Household energy bill drop ‘short-lived respite’ amid fears of July hike

Published

on

Household energy bill drop ‘short-lived respite’ amid fears of July hike



Household energy prices are falling by 7% from Wednesday in a “short-lived respite” for households already braced for a predicted 18% hike from July.

Ofgem’s price cap has dropped from £1,758 to £1,641 – a reduction of £117 or around £10 a month for the average household using both electricity and gas.

This is an 11% fall year on year, but still £600 more than bills were in the winter of 2020 to 2021.

The reduction is lower than the average £150 cut to bills pledged by the Chancellor in November, when she moved 75% of the cost of the renewables obligation from household bills onto general taxation and scrapped the energy company obligation (Eco) scheme.

And it comes amid increasing concern about the amount energy bills could rise by from July as a result of the Middle East conflict, with latest predictions from Cornwall Insight suggesting this could be 18% or £288 a year – to almost £900 above pre-crisis levels.

In the meantime, consumer groups have urged households to send in meter readings to ensure their energy usage is billed at the lowest possible rate, and investigate fixed rate deals if they remain on their firm’s standard variable rate.

A spokesman for Energy UK, which represents firms, said: “Suppliers are required to set direct debits as accurately as possible based on the best and most current information available.

“So – as well as factors like current balance, payment record and previous energy usage – this will also include the latest projection of energy costs over the coming months.

“Suppliers regularly review direct debt levels so any current assessment for price cap customers would likely take into account that bills look set to go up again in July. Customers on fixed deals however will not see any increase until their current deal comes to an end.”

Simon Francis, coordinator of the End Fuel Poverty Coalition, said: “The fall in bills from April 1 offers brief relief for households, but the respite will be short-lived.

“Given the ongoing profits made by the energy industry, households deserve more than a temporary reprieve before prices rise again.

“For the millions of households already in energy debt to their suppliers, this is a real concern and risks pushing more people into crisis.

“The Government must use the window between now and July to act. That means targeted support for those hit first and hardest, including households off the gas grid and those on heat networks, faster action on energy debt, and preparations to bring costs down if prices deteriorate further.”

National Energy Action chief executive Adam Scorer said: “Any price drop is good news, but everyone knows that it will be overtaken by events.

“It is likely to be a false dawn. And the people who know that the best are those already struggling to afford their energy bills and know the real cost of an energy crisis.

“Unfortunately, today’s good news is hugely overshadowed by the fear and dread of what may be to come.”

Which? energy editor Emily Seymour said: “April’s energy price cap fall will bring much needed relief for households. What you save will vary depending on how much you use.

“Despite this drop, many households are already concerned about the next price cap announcement in May, which will set rates from July and is currently predicted to rise by £288, or 18%, per year for the average household.

“It’s important to remember this isn’t confirmed yet, so don’t feel pressured into making quick decisions.

“If you’re currently paying variable rates, it’s worth checking the market to see what fixed deals are available. Fixing could offer protection against future increases, but only if the price is right.

“Options have reduced in the last few weeks, but some energy companies are still offering fixes with prices around those of the January-March price cap.

“If you’re worried about paying your energy bills, contact your supplier as soon as possible. Energy companies are obliged to help if you’re struggling to pay and won’t disconnect you for missing a payment. Request a review or break in payments, and access any available hardship funds.”



Source link

Continue Reading

Business

Nike shares fall 9% on weak outlook, expected 20% sales decline in China

Published

on

Nike shares fall 9% on weak outlook, expected 20% sales decline in China


A Nike logo is displayed at a Nike store in Austin, Texas, Feb. 5, 2026.

Brandon Bell | Getty Images

Shares of Nike fell in extended trading Tuesday after the retailer warned sales will fall for the rest of the calendar year, led by an expected 20% decline in its key China market during the current quarter.

Chief Financial Officer Matt Friend said during the company’s earnings call that Nike expects sales for its current fiscal fourth quarter to drop between 2% and 4%, compared with Wall Street estimates of a 1.9% increase, according to LSEG.

For the duration of the calendar year, Friend said, the company expects sales to fall by a low single-digit percentage, led by growth in North America and offset by declines in China. That outlook wasn’t comparable to estimates.

Nike beat expectations across the business on both the top and bottom lines for its fiscal third quarter, but its guidance left investors with more questions about how long its turnaround will take. Friend also cautioned that Nike’s guidance was based off of where the global economic picture stands today — and it could change given recent geopolitical volatility.

“We also recognize that the environment around us has become increasingly dynamic, and we could experience unplanned volatility due to the disruption in the Middle East, rising oil prices and other factors that could impact either input costs or consumer behavior,” said Friend. “We are focused on what we can control.”

Shares fell more than 8% in extended trading.

Here’s how the world’s largest sneaker company did for its fiscal third quarter, compared with estimates from analysts polled by LSEG:

  • Earnings per share: 35 cents vs. 28 cents expected
  • Revenue: $11.28 billion vs. $11.24 billion expected

The company’s reported net income for the three-month period that ended Feb. 28 was $520 million, or 35 cents per share. That’s a 35% decline from $794 million, or 54 cents per share, a year earlier. That plunge came as Nike’s gross profit margin slid 1.3 percentage points to 40.2%, “primarily due to higher tariffs in North America,” the company said.

Sales were flat at $11.28 billion, compared to $11.27 billion last year.

While Nike beat expectations on the top and bottom lines, it posted a mixed picture regionally. Nike’s largest market of North America continued to show steady growth, as revenue climbed 3% to $5.03 billion, but that was just shy of Wall Street’s expectations of $5.04 billion, according to StreetAccount.

Meanwhile, Nike’s Greater China market continued to shrink, with revenue down 7% to $1.62 billion during the quarter. Still, that total beat analyst estimates of $1.50 billion, according to StreetAccount.

Nike is continuing to work through a colossal turnaround under CEO Elliott Hill. About a year and a half into his tenure, Hill has made strides in repairing parts of the business, but has been clear that it’ll take time for the entire company to improve given the retailer’s scale and complexity. 

He reiterated that expectation on Tuesday, saying in a news release that “the pace of progress is different across the portfolio.”

“The areas we prioritized first continue to drive momentum,” Hill said. “The work is not finished, but the direction is clear, our teams are moving with focus and urgency, and our foundation is getting even stronger to build the future of NIKE.”

Friend said Nike’s turnaround efforts “will continue to impact results over the balance of the calendar year.”

Nike’s recovery was already coming at a tough time as a global trade war dented its efforts to improve profitability and drive sales from inflation-weary shoppers. But now the athletic company will have to contend with a new war in the Middle East that’s already led to rising gas prices and is expected to send consumer prices even higher, which could push shoppers to cut back on nice-to-haves like new clothes and shoes to save money elsewhere. 

“We continue to be encouraged by the momentum in North America. We’ve got a strong order book for summer,” Friend said. “We’re seeing positive signs and sell through. We’re not seeing a consumer reaction to what’s going on in the Middle East at this point in time, in North America.”

Hill has focused in part on revitalizing Nike’s business with wholesale partners as opposed to direct sales on its website and in stores. Wholesale revenue climbed 5% to $6.5 billion.

Meanwhile, direct sales slid 4% to $4.5 billion.

Choose CNBC as your preferred source on Google and never miss a moment from the most trusted name in business news.



Source link

Continue Reading

Trending